Early PKD Observational Cohort Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

NCT03493802

Autosomal Dominant Polycystic Kidney Disease

COMPLETED

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

NCT00327860

Chronic Kidney Disease

RECRUITING

Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease

NCT06688981

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ACTIVE_NOT_RECRUITING

ADPKD Alterations in Hepatic Transporter Function

NCT03717883

ADPKD Autosomal Dominant Polycystic Kidney Disease Renal Disease

COMPLETED

Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping

NCT02161068

ADPKD

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In polycystic kidney disease (PKD), renal cysts form in utero and progressively enlarge due to aberrant proliferation of the cyst-lining cells and accumulation of fluid within the expanding cyst cavity. Over decades of unrelenting cyst growth, renal function declines due to the loss of functional tissue, eventually leading to kidney failure and the need for renal replacement therapy, such as dialysis or kidney transplantation.

Effective therapies for the treatment of PKD will need to be delivered as early as possible, before a measurable decline in kidney function, to preserve functional tissue. Currently, it is difficult to make an accurate prognosis of the progression of early-stage PKD since the growth of microscopic cysts is difficult to detect by standard imaging modalities and changes in total kidney volume measured within a reasonable time period are too small to be informative. Even though early cysts may not cause detectable changes in total kidney volume, their progressive enlargement damages the surrounding tissue and is a prelude to chronic kidney disease.

Current blood and urine tests provide important information on the decline of kidney function; however, these tests are not useful for monitoring early events of PKD such as initial cyst growth and damage to neighboring tissue. Clearly, novel biomarkers of early cystic disease need to be discovered to develop appropriate clinical tests to monitor the progression of early stage PKD. These tests will be important to identify patients at risk of rapid progression and of need of therapeutic intervention and to monitor the effectiveness of the therapeutic drug. The PKD Biomarkers Repository will allow approved researchers to obtain blood and urine samples for biomarker discovery and development of appropriate biomarker assays for prognosis of early PKD.

This observational study is currently recruiting for three groups: 1) individuals diagnosed with relatively early PKD as defined by total kidney volume and estimated GFR, 2) unaffected or undiagnosed family members, preferably siblings, 3) normal volunteers with no family history of renal disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Individuals diagnosed with PKD

Individuals that have been diagnosed and meet the study's definition of early stage PKD.

No interventions assigned to this group

Individuals with a family history of PKD

Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD

No interventions assigned to this group

Normal individuals for the comparison

Normal volunteers with no family history of PKD or other kidney diseases.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD):

* Family history of PKD
* All races and ethnic groups
* Glomerular filtration rate (GFR) \>80 ml/min per 1.73 m2
* Inclusion for Healthy Volunteers:

* Male or female with no family history of kidney disease
* All races and ethnic groups
* Normal GFR

Exclusion Criteria

* Non-insulin or insulin-dependent diabetes mellitus
* Systemic illness (i.e.systemic lupus erythematosus, vasculitis)
* Unable to provide written informed consent
* Unavailable for magnetic resonance imaging (MRI) and blood/urine collection

Minimum Eligible Age

4 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes